Rasmussen MH
Global Development,
Novo Nordisk A/S, DK-2860 Søborg
Denmark
Research Article
Growth Hormone Bioavailability, Insulin-Like Growth Factor-I and IGFBinding-Protein-3 Release in Japanese and Caucasian Subjects
Author(s): Rasmussen MH, Jøns K, Christiansen T and Madsen JRasmussen MH, Jøns K, Christiansen T and Madsen J
Context: The pharmacokinetics (PK) of the recombinant human GH (rhGH) is poorly documented for the Japanese adult population, and a study comparing the PK, insulin-like growth factor-I (IGF-I) and IGF-bindingprotein- 3 (IGFBP-3) release between Japanese and Caucasian subjects after rhGH administration has previously not been reported.
Objective: To compare the profiles of serum GH concentrations and the IGF-I and IGFBP-3 responses after administration of identical doses of rhGH to healthy Japanese and Caucasian subjects.
Design and Setting: A randomised, double-blind, placebo-controlled, parallel-group study.
Participants and Intervention: A total of 80 healthy male subjects (40 Japanese and 40 Caucasians) completed the study. A single dose of rhGH or placebo was administered subcutaneously, and blood samples were drawn up to 24 hours post-administration.
M.. View More»
DOI:
10.4172/jbb.1000211